Literature DB >> 22896618

Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains.

Madelyn R Schmidt1, Lori W McGinnes, Sarah A Kenward, Kristen N Willems, Robert T Woodland, Trudy G Morrison.   

Abstract

Although respiratory syncytial virus (RSV) is a significant human pathogen, no RSV vaccines are available. We have reported that a virus-like particle (VLP) RSV vaccine candidate stimulated, in mice, robust, protective anti-RSV glycoprotein T(H)1 biased immune responses without enhanced respiratory disease upon RSV challenge. We report here an analysis of long-term responses to these VLPs. BALB/c mice immunized, without adjuvant, with VLPs or with infectious RSV generated anti-F and anti-G protein serum antibody responses that were stable over 14 months. Neutralizing antibody titers stimulated by VLPs were robust and durable for 14 months, whereas those of RSV-immunized animals declined significantly by 3 months. F protein-specific antibody-secreting cells were detected in the bone marrows of VLP-immunized mice but not in the marrows of RSV-immunized mice. Adoptive transfer of enriched splenic B cells from VLP-immunized mice into immunodeficient rag(-/-) mice resulted in anti-F and anti-G protein serum IgG antibody responses, in recipient mice, that were protective upon RSV challenge. In contrast, transfer of splenic B cells from RSV-immunized mice produced no detectable serum antibody in the recipients, nor could these mice inhibit RSV replication upon virus challenge. Immunization with VLPs stimulated the formation of germinal center GL7(+) B cells in normal mice. VLP immunization of TCR βδ(-/-) T-cell-deficient mice did not induce anti-RSV IgG antibodies, results consistent with T-cell-dependent immune responses. These results demonstrate that VLPs are effective in stimulating long-lived RSV-specific, T-cell-dependent neutralizing antibody-secreting cells and RSV-specific memory responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896618      PMCID: PMC3486317          DOI: 10.1128/JVI.01510-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Role of Toll-like receptors in costimulating cytotoxic T cell responses.

Authors:  Katrin Schwarz; Tazio Storni; Vania Manolova; Arnaud Didierlaurent; Jean-Claude Sirard; Peter Röthlisberger; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

Review 2.  Virus-like particles as immunogens.

Authors:  Rob Noad; Polly Roy
Journal:  Trends Microbiol       Date:  2003-09       Impact factor: 17.079

Review 3.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

4.  Persistence of memory B cells in mice deprived of T cell help.

Authors:  P Vieira; K Rajewsky
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

5.  Requirements for budding of paramyxovirus simian virus 5 virus-like particles.

Authors:  Anthony P Schmitt; George P Leser; David L Waning; Robert A Lamb
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Respiratory tract viral infections in bone marrow transplant patients.

Authors:  Sonia M Raboni; Meri B Nogueira; Luine R V Tsuchiya; Gislene A Takahashi; Luciane A Pereira; Ricardo Pasquini; Marilda M Siqueira
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

Review 8.  Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.

Authors:  Ultan F Power
Journal:  J Clin Virol       Date:  2008-01       Impact factor: 3.168

9.  Stimulation of a memory B cell response does not require primed helper T cells.

Authors:  C Leclerc; C Sedlik; R Lo-Man; B Charlot; M Rojas; E Dériaud
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

10.  Activation of virus-specific memory B cells in the absence of T cell help.

Authors:  Barbara J Hebeis; Karin Klenovsek; Peter Rohwer; Uwe Ritter; Andrea Schneider; Michael Mach; Thomas H Winkler
Journal:  J Exp Med       Date:  2004-02-09       Impact factor: 14.307

View more
  20 in total

1.  Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Trudy G Morrison
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

2.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

3.  Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.

Authors:  Hye Suk Hwang; Young-Man Kwon; Jong Seok Lee; Si-Eun Yoo; Yu-Na Lee; Eun-Ju Ko; Min-Chul Kim; Min-Kyoung Cho; Young-Tae Lee; Yu-Jin Jung; Ji-Yun Lee; Jian-Dong Li; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

4.  Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Authors:  Sujin Lee; Fu-Shi Quan; Youngman Kwon; Kaori Sakamoto; Sang-Moo Kang; Richard W Compans; Martin L Moore
Journal:  Antiviral Res       Date:  2014-09-18       Impact factor: 5.970

Review 5.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Authors:  Cameron Griffiths; Steven J Drews; David J Marchant
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

6.  A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Authors:  Dai Wang; Shannon Phan; Daniel J DiStefano; Michael P Citron; Cheryl L Callahan; Lani Indrawati; Sheri A Dubey; Gwendolyn J Heidecker; Dhanasekaran Govindarajan; Xiaoping Liang; Biao He; Amy S Espeseth
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

7.  Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.

Authors:  Youri Lee; Young-Tae Lee; Eun-Ju Ko; Ki-Hye Kim; Hye Suk Hwang; Soojin Park; Young-Man Kwon; Sang Moo Kang
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

8.  Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Authors:  Madelyn R Schmidt; Lori W McGinnes-Cullen; Sarah A Kenward; Kristin N Willems; Robert T Woodland; Trudy G Morrison
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

9.  The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.

Authors:  Chetan D Meshram; Pradyumna S Baviskar; Cherie M Ognibene; Antonius G P Oomens
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

10.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.